Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.05 Billion KRW | -24.56% |
| 2022 | 2.31 Billion KRW | -77.12% |
| 2021 | 10.09 Billion KRW | 19.03% |
| 2020 | 8.48 Billion KRW | -50.35% |
| 2019 | 17.08 Billion KRW | 212.21% |
| 2018 | 5.47 Billion KRW | 54.63% |
| 2017 | 3.54 Billion KRW | 1140.37% |
| 2016 | 285.4 Million KRW | 106.67% |
| 2015 | -4.27 Billion KRW | -624.98% |
| 2014 | 815.26 Million KRW | 106.28% |
| 2013 | -12.98 Billion KRW | -323.84% |
| 2012 | -3.06 Billion KRW | 69.42% |
| 2011 | -10.01 Billion KRW | -246.33% |
| 2010 | 6.84 Billion KRW | 70.4% |
| 2009 | 4.01 Billion KRW | 249.6% |
| 2008 | 1.14 Billion KRW | 170.71% |
| 2007 | -1.62 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 119 Million KRW | 102.69% |
| 2024 Q2 | -3.05 Billion KRW | -2668.91% |
| 2024 Q3 | 430 Million KRW | 114.07% |
| 2023 Q3 | 91.21 Million KRW | -98.88% |
| 2023 Q4 | -4.41 Billion KRW | -4945.25% |
| 2023 Q2 | 8.12 Billion KRW | 567.23% |
| 2023 Q1 | -1.73 Billion KRW | -318.85% |
| 2023 FY | 1.74 Billion KRW | -24.56% |
| 2022 Q1 | -374.67 Million KRW | -140.53% |
| 2022 Q3 | 621.84 Million KRW | -47.36% |
| 2022 Q4 | 794.3 Million KRW | 27.73% |
| 2022 FY | 2.31 Billion KRW | -77.12% |
| 2022 Q2 | 1.18 Billion KRW | 415.32% |
| 2021 Q1 | 5.39 Billion KRW | 1112.17% |
| 2021 Q3 | 2.2 Billion KRW | 40.41% |
| 2021 Q4 | 924.37 Million KRW | -58.12% |
| 2021 Q2 | 1.57 Billion KRW | -70.87% |
| 2021 FY | 10.09 Billion KRW | 19.03% |
| 2020 FY | 8.48 Billion KRW | -50.35% |
| 2020 Q2 | 1.61 Billion KRW | -43.14% |
| 2020 Q3 | 1.03 Billion KRW | -36.18% |
| 2020 Q1 | 2.84 Billion KRW | -5.3% |
| 2020 Q4 | 445.12 Million KRW | -56.85% |
| 2019 FY | 17.08 Billion KRW | 212.21% |
| 2019 Q2 | 7 Billion KRW | 174.58% |
| 2019 Q3 | 4.53 Billion KRW | -35.33% |
| 2019 Q4 | 3 Billion KRW | -33.76% |
| 2019 Q1 | 2.55 Billion KRW | 74.76% |
| 2018 Q2 | 1.6 Billion KRW | 479.67% |
| 2018 FY | 5.47 Billion KRW | 54.63% |
| 2018 Q4 | 1.46 Billion KRW | -31.5% |
| 2018 Q3 | 2.13 Billion KRW | 32.77% |
| 2018 Q1 | 276.94 Million KRW | -86.67% |
| 2017 Q1 | -851.97 Million KRW | 20.02% |
| 2017 Q4 | 2.07 Billion KRW | 0.89% |
| 2017 FY | 3.54 Billion KRW | 1140.37% |
| 2017 Q2 | 256.41 Million KRW | 130.1% |
| 2017 Q3 | 2.05 Billion KRW | 702.87% |
| 2016 Q4 | -1.06 Billion KRW | 2.38% |
| 2016 FY | 285.4 Million KRW | 106.67% |
| 2016 Q1 | 1.69 Billion KRW | 184.7% |
| 2016 Q2 | 743.34 Million KRW | -56.23% |
| 2016 Q3 | -1.09 Billion KRW | -246.79% |
| 2015 Q4 | -2 Billion KRW | 20.0% |
| 2015 Q2 | 127.95 Million KRW | 23.18% |
| 2015 Q3 | -2.5 Billion KRW | -2059.0% |
| 2015 Q1 | 103.87 Million KRW | 26.11% |
| 2015 FY | -4.27 Billion KRW | -624.98% |
| 2014 Q3 | 90.07 Million KRW | -84.84% |
| 2014 FY | 815.26 Million KRW | 106.28% |
| 2014 Q1 | 48.87 Million KRW | 100.9% |
| 2014 Q4 | 82.36 Million KRW | -8.55% |
| 2014 Q2 | 593.95 Million KRW | 1115.38% |
| 2013 FY | -12.98 Billion KRW | -323.84% |
| 2013 Q4 | -5.43 Billion KRW | -54.55% |
| 2013 Q3 | -3.51 Billion KRW | -56.15% |
| 2013 Q2 | -2.25 Billion KRW | -26.2% |
| 2013 Q1 | -1.78 Billion KRW | 3.16% |
| 2012 Q2 | -1.4 Billion KRW | -966.2% |
| 2012 FY | -3.06 Billion KRW | 69.42% |
| 2012 Q4 | -1.84 Billion KRW | -284.91% |
| 2012 Q3 | 996.08 Million KRW | 171.1% |
| 2012 Q1 | -131.39 Million KRW | 0.0% |
| 2011 Q2 | -5.54 Billion KRW | -526.64% |
| 2011 FY | -10.01 Billion KRW | -246.33% |
| 2011 Q1 | 1.3 Billion KRW | -59.79% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 Q3 | -1.79 Billion KRW | 67.58% |
| 2010 Q1 | 503.48 Million KRW | -73.45% |
| 2010 FY | 6.84 Billion KRW | 70.4% |
| 2010 Q4 | 3.23 Billion KRW | 140.86% |
| 2010 Q3 | 1.34 Billion KRW | -24.04% |
| 2010 Q2 | 1.76 Billion KRW | 251.01% |
| 2009 Q2 | 1.1 Billion KRW | 42.61% |
| 2009 Q1 | 773.7 Million KRW | -24.42% |
| 2009 Q3 | 244.4 Million KRW | -77.85% |
| 2009 Q4 | 1.89 Billion KRW | 675.92% |
| 2009 FY | 4.01 Billion KRW | 249.6% |
| 2008 Q3 | 371.74 Million KRW | 66.59% |
| 2008 Q4 | 1.02 Billion KRW | 175.39% |
| 2008 FY | 1.14 Billion KRW | 170.71% |
| 2008 Q1 | -469.34 Million KRW | 7.75% |
| 2008 Q2 | 223.14 Million KRW | 147.54% |
| 2007 FY | -1.62 Billion KRW | 0.0% |
| 2007 Q2 | 266.02 Million KRW | 119.01% |
| 2007 Q3 | 17.11 Million KRW | -93.57% |
| 2007 Q1 | -1.39 Billion KRW | 0.0% |
| 2007 Q4 | -508.75 Million KRW | -3073.09% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -738.34% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 96.025% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 103.841% |
| HANDOK Inc. | 12.57 Billion KRW | 75.705% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 253.637% |
| Yuhan Corporation | 74.56 Billion KRW | 95.901% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 72.661% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 116.938% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 98.641% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 78.704% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -412.415% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -217.096% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 88.694% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -738.34% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 139.402% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 24.235% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 104.369% |
| JW Holdings Corporation | 143.66 Billion KRW | 97.873% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 105.721% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 98.761% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 96.953% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 106.448% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 55.881% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 52.773% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 64.999% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -738.34% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 93.733% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 97.709% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 96.953% |
| Yuhan Corporation | 74.56 Billion KRW | 95.901% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 85.392% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 1.968% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 92.892% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 96.953% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 85.081% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 94.438% |
| CKD Bio Corp. | -20.15 Billion KRW | 115.165% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 90.519% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 87.922% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 90.604% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 106.448% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 90.78% |
| Boryung Corporation | 68.26 Billion KRW | 95.523% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 108.15% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 78.704% |
| JW Lifescience Corporation | 32.09 Billion KRW | 90.477% |